Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06302621 · ClinicalTrials.gov registry record · Phase 1
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Cholangiocarcinoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06302621: Recruiting Phase 1 study of Advanced Solid Tumor and Cholangiocarcinoma, sponsored by Massachusetts General Hospital.
NCT06302621 is a Phase 1 study of Advanced Solid Tumor and Cholangiocarcinoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 70 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06302621, a Phase 1 study of Advanced Solid Tumor and Cholangiocarcinoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable side effects. This research study involves the study drugs Afatinib and Pemigatinib.
Primary Outcome
All patients in the dose-escalation part who have received ≥ 75% (21 days) of study drug and completed Cycle 1 through Cycle 1 Day 21 or experienced a dose limiting toxicity (DLT)
Conditions Studied
Interventions
- DRUG Afatinib
- DRUG Pemigatinib
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
What NCT06302621 shows while recruiting
NCT06302621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (64% lower).
The record links to 4 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Afatinib is the first listed.
NCT06302621 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06302621 about?
NCT06302621 is a clinical study titled "Pemigatinib + Afatinib in Advanced Refractory Solid Tumors". This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable si...
What is the current status of trial NCT06302621?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2024-04-17. Estimated completion is 2027-12-01.
What conditions does trial NCT06302621 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Cholangiocarcinoma, Metastatic Solid Tumor, Unresectable Solid Tumor.
What interventions are being tested in trial NCT06302621?
The interventions under investigation include: Afatinib (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT06302621?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06302621 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06302621's enrollment target sits among peer trials
70 142nd of 189 higher than 42 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI